Skip to main content

Table 3 Association between statin therapy and hospital mortality, stratified by different relevant characteristics

From: Association between statin therapy and outcomes in critically ill patients: a nested cohort study

 

Statin

n = 107

Non-statin

n = 656

Adjusted odds ratio (aOR)a

95% confidence interval

P-value

Hospital mortality, no. (%)

42/107 (39.3)

200/656 (30.5)

0.60

(0.36 - 0.99)

0.05

Stratified by age, no. (%)

     

   ≤ 58 yrs

6/14 (42.9)

62/374 (16.6)

0.73

(0.19 - 2.81)

0.64

   > 58 yrs

36/93 (38.7)

138/282 (49.0)

0.58

(0.35 - 0.97)

0.04

Gender, no. (%)

     

   Male

21/63 (33.3)

126/492 (25.6)

0.56

(0.29 - 1.08)

0.08

   Female

21/44 (47.7)

74/164 (45.0)

0.74

(0.35 - 1.58)

0.43

Admission category, no. (%)

     

   Postoperative

1/4 (25.0)

19/119 (16.0)

0.75

(0.04 - 14.82)

0.85

   Nonoperative

41/103 (40.0)

181/537 (34.0)

0.62

(0.34 - 1.03)

0.06

APACHE II, no. (%)

     

   APACHE≤ 22

8/33 (24.2)

53/370 (14.3)

0.77

(0.27 - 2.21)

0.63

   APACHE>22

34/74 (46.0)

147/286 (51.4)

0.54

(0.31 - 0.96)

0.03

SOFA, no. (%)

     

   ≤ 9

13/58 (22.4)

63/346 (18.2)

0.55

(0.26 - 1.17)

0.12

   > 9

29/49 (59.1)

137/310 (44.2)

0.73

(0.36 - 1.48)

0.38

History of diabetes, no. (%)

     

   Yes

31/84 (37.0)

106/209 (48.4)

0.52

(0.30 - 0.90)

0.02

   No

11/23 (47.8)

94/437 (21.5)

1.31

(0.49 - 3.54)

0.59

History of cardiovascular, no. (%)

     

   Yes

23/54 (42.6)

58/103 (56.3)

0.59

(0.3 - 1.2)

0.13

   No

19/53 (35.9)

142/553 (25.7)

0.52

(0.27 - 1)

0.06

Vasopressor therapy, no. (%)

     

   Yes

31/73 (42.5)

151/423 (35.7)

0.53

(0.29 - 0.97)

0.04

   No

23/34 (67.7)

184/233 (79.0)

0.92

(0.37 - 2.25)

0.84

Sepsis, no. (%)

     

   Yes

12/28 (43.0)

88/166 (53.0)

0.64

(0.26 - 1.58)

0.33

   No

30/79 (38.0)

112/490 (23.0)

0.72

(0.41 - 1.28)

0.26

Severe sepsis and septic shock no. (%)

     

   Yes

14/26 (53.9)

84/207 (40.6)

0.22

(0.07 - 0.66

0.007

   No

28/81 (34.6)

116/449 (25.7)

0.78

(0.45 - 1.37)

0.38

Creatinine, no. (%)

     

   ≤ 100 μmol/L

4/26 (15.4)

70/351 (20.0)

0.14

(0.04 - 0.51)

0.002

   > 100 μmol/L

38/81 (47.0)

130/305 (43.0)

1.01

(0.58 - 1.77)

0.96

Platelets, no. (%)

     

   ≤ 180

12/25 (48.0)

125/358 (35.0)

0.62

(0.24 - 1.62)

0.33

   > 180

30/82 (36.6)

75/298 (25.2)

0.78

(0.43 - 1.42)

0.42

Bilirubin, no. (%)

     

   ≤ 16 μmol/L

10/38 (26.3)

54/212 (25.5)

0.49

(0.21 - 1.20)

0.11

   > 16 μmol/L

10/22 (45.5)

73/223 (32.7)

0.67

(0.23 - 1.97)

0.47

INR, no. (%)

     

   ≤1.2

20/59 (34.0)

68/312 (21.8)

0.79

(0.40 - 1.58)

0.51

   >1.2

22/48 (45.8)

132/344 (38.4)

0.53

(0.26 - 1.09)

0.09

GCS, no. (%)

     

   ≤ 9

19/50 (38.0)

114/364 (31.3)

0.34

(0.17 - 0.71)

0.004

   > 9

23/57 (40.4)

86/292 (29.5)

092

(0.46 - 1.85)

0.81

Length of stay, no. (%)

     

   ≤ 5 days

4/39 (10.3)

32/192 (16.7)

0.40

(0.13 - 1.28)

0.12

   > 5 days

38/68 (55.9)

168/464 (36.2)

0.63

(0.34 - 1.19)

0.16

Mechanical ventilation, no. (%)

     

   Yes

40/92 (43.5)

183/591 (31.0)

0.66

(0.34 - 1.10)

0.11

   No

2/15 (13.3)

17/65 (26.2)

0.75

(0.09 - 6.43)

0.79

Simvastatin, no. (%)

12/44 (27.3)

200/656 (30.5)

0.37

(0.17 - 0.81)

0.01

Atorvastatin, no. (%)

30/63 (47.6)

200/656 (30.5)

0.80

(0.84 - 1.46)

0.47

  1. APACHE II: Acute physiology and chronic health evaluation II; SOFA: Sequential organ failure assessment; INR: International normalised ratio; GCS: Glasgow coma scale.
  2. *To convert units to mg/dl, divide by 88.4 for creatinine and 17.1 for bilirubin